Trevi Therapeutics (TRVI) Net Cash Flow (2018 - 2026)
Trevi Therapeutics (TRVI) posted quarterly Net Cash Flow of $498000.0 for Q1 2026, up 103.38% year-over-year from $244858.9 in Q1 2025, and up 101.31% quarter-over-quarter from -$38.0 million in Q4 2025.
Trevi Therapeutics (TRVI) Net Cash Flow (2018 - 2026) Analysis & Trends
Trevi Therapeutics' Net Cash Flow history runs 9 years deep, the most recent figure standing at $498000.0 for Q1 2026.
- In Q1 2026, Net Cash Flow rose 103.38% year-over-year to $498000.0; the TTM figure through Mar 2026 stood at $38000.0 (down 99.32% YoY), while the FY2025 annual figure was -$15.2 million, down 993.12% from the prior year.
- Net Cash Flow for Q1 2026 stood at $498000.0, up from -$38.0 million in the prior quarter.
- The five-year high for Net Cash Flow was $97.7 million in Q2 2025, with the low at -$60.2 million in Q3 2025.
- The 5-year median for Net Cash Flow is $498000.0 (2026), against an average of $2.2 million.
- Peak annual rise in Net Cash Flow reached 11619.34% in 2025, while the deepest fall reached 2048.49% in 2025.
- Trevi Therapeutics' Net Cash Flow stood at -$54.0 million in 2022, then soared by 111.91% to $6.4 million in 2023, then surged by 180.55% to $18.0 million in 2024, then sank by 310.34% to -$38.0 million in 2025, then soared by 101.31% to $498000.0 in 2026.
- Business Quant data shows TRVI's Net Cash Flow at $498000.0 in Q1 2026, -$38.0 million in Q4 2025, and -$60.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Trevi Therapeutics | 2.63 Bn | 2.63 Bn | - | 34.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.89 Mn |
| Jun 30, 2026 | 34.89 Mn |
| Mar 31, 2026 | 498,000.00 |
| Mar 31, 2026 | 498,000.00 |
| Dec 31, 2025 | -37.96 Mn |
| Dec 31, 2025 | -37.96 Mn |
| Sep 30, 2025 | -60.19 Mn |
| Sep 30, 2025 | -60.19 Mn |
| Jun 30, 2025 | 97.68 Mn |
| Jun 30, 2025 | 97.68 Mn |
| Mar 31, 2025 | -14.72 Mn |
| Mar 31, 2025 | -14.72 Mn |
| Dec 31, 2024 | 18.05 Mn |
| Dec 31, 2024 | 18.05 Mn |
| Sep 30, 2024 | 3.09 Mn |
| Sep 30, 2024 | 3.09 Mn |
| Jun 30, 2024 | -848,000.00 |
| Jun 30, 2024 | -848,000.00 |
| Mar 31, 2024 | -18.59 Mn |
| Mar 31, 2024 | -18.59 Mn |